Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine names James Mullen as chairman

He has previously served as CEO of Patheon

Jim MullenGenome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.

Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.

“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”

In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.

12th April 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics